Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on each patient’s clinical condition when determining initial treatment, ...

Healthcare stocks can provide growth and consistent returns through a variety of market cycles. Eli Lilly has a storied ...

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless”.

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...

The U.S. stock market sank from record heights as Wall Street sifted through mixed developments on everything from the ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...

A new partnership between Walmart and drug maker Eli Lily will make it easier for people to access the super-popular weight loss drug Zepbound. Starting in mid-November, customers with a prescription ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Eli Lilly has once again delivered extraordinary financial results, powered by its highly successful diabetes and obesity treatments. The pharmaceutical giant's third-quarter performance has left ...

These growth stocks are highly profitable and evolving in their respective industries. Eli Lilly is famed for its weight-loss medications, but it is more than just a GLP-1 play. MercadoLibre is a ...